Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $4.52M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 7,886 shares of United Therapeutics Corp at $556.52 to $582.79 a share (average $572.69) in 24 transactions, worth $4.52M in total on Nov 9, 2026. Shares held after the trade: 326,057 (-0.5%).
Big Sky Industrial Inc. reported a net loss of $9.0 million for the nine months ended September 30, 2026, compared to a $12.5 million loss in the prior year period. The company significantly increased its unproved industrial gas properties to $42.5 million and expanded its common stock outstanding to 52.5 million shares following an underwritten offering.
Motorola Solutions SVP, General Counsel James A. Niewiara Sells $1.18M of Stock
James A. Niewiara, SVP, General Counsel, sold 2,266 shares of Motorola Solutions, Inc. at $515.16 to $522.35 a share (average $521.77) in 2 transactions, worth $1.18M in total between Nov 6, 2026 and Nov 9, 2026. Shares held after the trade: 18,398 (-10.2%).
VineBrook Homes Trust, Inc. reported a significant increase in real estate held for sale, rising from $91.5 million at the end of 2025 to $239.9 million as of September 30, 2026, as part of a strategy to sell approximately 2,725 homes to satisfy upcoming debt obligations. The company's total net real estate investments decreased to $2.65 billion, and it faces new regulatory risks from the 21st Century ROAD to Housing Act enacted in July 2026.
Central Pacific Financial Corp. announced a temporary blackout period for its directors and executive officers from December 18 to December 24, 2026. The restriction is due to the removal and liquidation of the company's stock fund as an investment option within the Central Pacific Bank 401(k) Retirement Savings Plan. During this window, covered persons are prohibited from trading in the company's common stock or derivative securities.
Fortitude Gold reported third quarter 2026 net sales of $10.3 million and net income of $2.0 million, or $0.07 per share. The company produced 2,139 gold ounces during the period and maintained a cash balance of $8.5 million while continuing permitting efforts for its Golden Mile property.
Term
3 months
“We had a very busy and productive third quarter including the ongoing expansion of our heap leach pad.”
United Therapeutics Director Christopher Patusky Sells $702K of Stock
Christopher Patusky, Director, sold 1,210 shares of United Therapeutics Corp at $580.00 a share, worth $702K in total on Nov 9, 2026. Shares held after the trade: 2,140 (-36.1%).
Auburn National Bancorporation, Inc. declared a fourth quarter cash dividend of $0.27 per share. The dividend is payable on December 28, 2026, to shareholders of record as of December 10, 2026.
Drew Lufkin, Senior Vice President of Sales at Beyond Meat, Inc., notified the company of his resignation effective November 20, 2026. The departure is to pursue another opportunity and is not due to any disagreement with the company's operations or policies.
Alto Neuroscience reported a net loss of $79.0 million for the nine months ended September 30, 2026, compared to $47.1 million in the prior year, driven by a significant increase in research and development expenses. The company strengthened its balance sheet through a private placement and direct shelf offering, ending the period with $319.3 million in cash and cash equivalents.
West Coast Community Bancorp reported net income of $43.9 million for the nine months ended September 30, 2026, an increase from $36.7 million in the prior year period. Total assets grew to $2.98 billion, driven by a $164.5 million increase in loans held for investment, while the company successfully retired its subordinated debentures during the period.
Zion Oil & Gas reported a net loss of $5.9 million for the nine months ended September 30, 2026, compared to $5.3 million in the prior year period. The company remains in the exploration phase with $38.4 million invested in unproved oil and gas properties and continues to fund operations primarily through the sale of common stock and exercise of warrants, raising $17.3 million during the first nine months of 2026.
Waters Corp reported a significant increase in total net revenues to $1.77 billion for the third quarter of 2026, driven by the BDS Business Acquisition. However, the company recorded a net loss of $127 million for the first nine months of 2026, primarily due to higher interest expenses and substantial amortization of purchased intangibles following the acquisition.
Lake Shore Bancorp reported net income of $6.4 million for the nine months ended September 30, 2026, an increase from $5.3 million in the prior year period, driven primarily by higher net interest income. Total assets grew slightly to $734.2 million, while the company experienced a significant unrealized loss on securities available for sale, impacting accumulated other comprehensive loss.
ClearOne, Inc. reported zero revenue for the quarter ended September 30, 2026, following the sale of its operating assets in late 2025. The company recorded a net loss of $0.7 million for the quarter and is currently focused on fulfilling legacy obligations and pursuing a merger with Cortigent, Inc. and Vivani Medical, Inc. while facing potential Nasdaq delisting.
Datacentrex, Inc. reported a net loss of $14.2 million for the nine months ended September 30, 2026, compared to a $3.4 million loss in the prior year period, driven by significantly higher depreciation and stock-based compensation. Despite the net loss, the company increased its total assets to $72.9 million, bolstered by a $30 million investment in ELNG Equity LLC and proceeds from a public offering.
Kopin Corp reported total revenues of $18.2 million for the quarter ended September 26, 2026, a significant increase from $12.0 million in the prior year, driven by higher research and development revenues and grant income. Despite the revenue growth, the company realized a net loss of $3.4 million for the quarter, compared to a net income of $4.1 million in the same period in 2025.
Clarivate Plc's subsidiary, Clarivate Science Holdings Corporation, announced the pricing terms for its cash tender offers to repurchase up to $533 million in aggregate principal amount of its outstanding 3.875% Senior Secured Notes due 2028 and 4.875% Senior Notes due 2029. The company exercised its right to increase the purchase caps for each series of notes by 2% of the outstanding aggregate principal amount.
Addus HomeCare EVP, Chief Information Officer Michael D. Wattenbarger Sells $887K of Stock
Michael D. Wattenbarger, EVP, Chief Information Officer, sold 7,111 shares of Addus HomeCare Corp at $124.38 to $125.20 a share (average $124.67) in 4 transactions, worth $887K in total on Nov 6, 2026. Shares held after the trade: 7,303 (-19.2%).
Marathon Bancorp reported net income of $452,896 for the quarter ended September 30, 2026, a slight increase from $444,293 in the prior year period. Total assets decreased slightly to $258.9 million, while total deposits grew by approximately $11.3 million during the quarter, offset by a $15 million reduction in FHLB advances.
Urban One reported a net revenue decrease of 5.0% to $88.0 million for Q3 2026, driven by adverse market conditions in radio and weak demand in the Cable TV scatter market. The company reported a significant net loss of $119.2 million, primarily due to a $128.9 million impairment charge on goodwill and intangible assets. Management lowered its full-year 2026 Adjusted EBITDA guidance to $40.0 million and identified $20.0 million in annualized cost savings for the upcoming year.
Term
3 months
“Market conditions in radio continued to adversely impact revenue in the third quarter. We were helped by net political revenue of over $0.8 million in the quarter and the acquisition of stations in our Dallas market, effective July 17th, which contributed an additional $1.9 million of net revenue in the quarter.”
Alfred C. Liggins, III, Urban One’s CEO and President
“Revised Adjusted EBITDA guide for 2026 is now $40.0 million given the realities of the current advertising marketplace. Management is hyper-focused on cost reductions heading into next year and has identified at least $20.0 million of annualized savings.”
Alfred C. Liggins, III, Urban One’s CEO and President
Addus HomeCare Chairman and CEO R. Dirk Allison Sells $12.2M of Stock
R. Dirk Allison, Chairman and CEO, sold 98,958 shares of Addus HomeCare Corp at $122.29 to $124.81 a share (average $123.27) in 4 transactions, worth $12.2M in total on Nov 9, 2026. Shares held after the trade: 183,150 (-0.1%).
LENSAR, Inc. is focused on the commercialization of its ALLY Robotic Cataract Laser System while navigating the aftermath of a terminated Merger Agreement. The company continues to report operating losses and emphasizes risks related to macroeconomic conditions, regulatory clearances, and patient willingness to pay for advanced cataract procedures.
Stran & Company, Inc. reported a net income of $1.09 million for the nine months ended September 30, 2026, compared to a net loss of $0.99 million in the prior year period. Total sales increased to $92.7 million from $87.3 million, while the company maintained a strong cash position of $7.38 million as of the end of the third quarter.
CNL Strategic Capital, LLC entered into an amended management agreement to reduce its fee structure effective January 1, 2027. The Base Management Fee for Non-Founder Shares will decrease from 2.0% to 1.5%, and the Total Return Incentive Fee will be lowered from 20% to 15%.
Motorola Solutions EVP and COO John P. Molloy Sells $21.1M of Stock
John P. Molloy, EVP and COO, sold 40,982 shares of Motorola Solutions, Inc. at $508.84 to $517.11 a share (average $514.45) in 9 transactions, worth $21.1M in total on Nov 6, 2026. Shares held after the trade: 69,330 (-1.4%).
Harvard Bioscience reported revenues of $22.2 million for Q3 2026, a slight increase from $20.6 million in the prior year, though the company recorded a net loss of $2.6 million. For the nine months ended September 30, 2026, the net loss was $9.0 million compared to a $53.9 million loss in 2025, which had been driven by a significant $48.0 million goodwill impairment charge.
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for diabetes and obesity. The filing indicates substantial doubt about the company's ability to continue as a going concern, highlighting a critical need for additional capital to fund ongoing research and development of its lead candidates, icovamenib and BMF-650.
Humacyte, Inc. reported a significant increase in cash and cash equivalents to $64.5 million as of September 30, 2026, following the commercialization of Symvess. The company recorded a litigation settlement liability of $9.75 million and an accumulated deficit of $796.8 million, while common stock outstanding grew to over 277 million shares.